Northwest Biotherapeutics Inc (QB) (NWBO) News

FeMike Maybe so, but it does show another big company investing in the US courtesy of DJT. Many more to follow.

Um, the Govt IS bankrupt.

Right? Acting like this Musk statement is something shocking. It's the equivalent of Arnold making a statement that pro bodybuilders are on steroids. Yeh, we know.

Merck & Co IncMerck Unveils New Facility to Increase Vaccine Production Capacity

I flagged this post as off topic because it has absolutely nothing to do with NWBO.

So you’d prefer the lies? That’s the beauty of this administration…Transparency, like it or not!

How could they have already unveiled. Per Dstock, those facilities were being built for DCVax. Are you saying he was wrong??!?! are we not partnering with Merck to build millions of DCVax doses? say it aint so

Is it Friday yet?

We might be better valued if the whole Toucan entanglement didn't muddy the waters

You forgot she executed her plan to dilute all shares of nwbo to fund her other investments. EXACTLY

Um, the Govt IS bankrupt. $2 Trillion deficit annually with all the ridiculous spending, fraud and abuse. $36 Trillion in debt not counting unfunded liabilities for a broken retirement system AND horrible healthcare administration. I would call that bankrupt.

There almost zero interest in the True-up suit here so I sincerely doubt anyone is coming to the rescue. Even Bigger doesn’t seem pissed that AF got the best of him.

Musk said, "The Gov't is bankrupt" in an interview I heard yesterday. He slipped IMO. It's not something his handlers would have authorized. Yellen announced it on January 20th, on her last day. If anyone thinks this is OT, they need their head examined.

Everyone is investing in Vaccines now that RFK Jr. in office! Nothing to see here folks, look the other way.

All that analysis and you left out the Advent equation. 🤷‍♀️

For kicks, Sawston is worth $400M, using a back of the envelope calculation by comparing the cost and sq footage of the Merck facility to Sawston. Merck's 225,000 sq ft facility cost $1 billion. Both are up to date vaccine facilities so somewhat an apple to apple comparison. Sawston has 88,345 sq ft making it 2.5 times smaller than Merck's facility. 2.5 times smaller than 1 billion is 400 million which is more than NWBOs MC (i.e. $329M). One of these days the market will recognize Sawston's value to NWBO.

If you had a cancer diagnosis, you’d not be asking such a stupid question. It’s coming and Karma’s a bitch.

try again on Merck news link:

insert-text-here

And here's another possible Merck manufacturing plant...

Delaware approves $30.2 million taxpayer-funded grant for Merck to build in state
Portrait of Molly McVety Molly McVety
Delaware News Journal
Pharmaceutical giant Merck may build a $900 million manufacturing facility near Greenville.
The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the Wilmington-area location.
If Merck accepts the grant, the company would be required to create 375 full-time jobs and operate the facility for at least 20 years.
Pharmaceutical giant Merck received a $30.2 million grant from the state in an effort to sway the company to build its $900 million manufacturing facility in the Wilmington area.

The taxpayer-funded grant is the highest amount that has been doled out to a company since Bloom Energy’s approval in 2011.

Merck & Co. has not confirmed whether or not it will choose Delaware as its place to expand, but business leaders in Delaware are optimistic about what the potential move could mean for the state.

Merck & Co. is a global health care company that specializes in the production and distribution of vaccines, pharmaceuticals and animal health care products.

Merck has been looking for a location to set up their newest manufacturing facility, which will produce drug substances and products with a targeted operational start date of 2030.According to plans shared with Delaware Online/The News Journal via a Freedom of Information Act request, the company is considering constructing a $900 million multi-building complex for labs, manufacturing and distribution operations at the Chestnut Run Innovation and Science Park near Greenville.

Under the conservative estimates listed in the plans, the facility would bring roughly 375 full-time jobs to the area.

You can find the link here: https://www.delawareonline.com/story/money/business/2025/03/06/merck-manufacturing-facility-delaware-council-development-finance-grant/81358137007/#:~:text=Pharmaceutical%20giant%20Merck%20received%20a,Bloom%20Energy's%20approval%20in%202011." rel="nofollow" target="_blank" >insert-text-here

Good for Merck , this has zero to do with NWBO.

Merck & Co IncMerck Unveils New Facility to Increase Vaccine Production Capacity
Mar 11 2025

Opening highlights effort to expand U.S. manufacturing through a $1 billion investment

DURHAM, N.C.--(BUSINESS WIRE)--Mar. 11, 2025-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site.

This expansion of our Durham plant is a crucial component of the more than $12 billionMerck has invested toward U.S. capital investment since 2018 focused on expanding domestic manufacturing and research and development capabilities and creating new jobs in the U.S., with another $8 billion of U.S. capital investment expected by 2028.

"Expanding our state-of-the-art manufacturing facility in Durham marks a significant milestone in our efforts to strengthen our production and manufacturing capabilities in the U.S.," said Sanat Chattopadhyay, executive vice president and president, Merck Manufacturing Division. "The cutting-edge technologies employed here empower our workforce and underscore our leadership in innovation to support patients everywhere."

The state-of-the-art manufacturing facility leverages best practices and learnings from across the Merck Manufacturing Division network as well as new technical and digital capabilities including data analytics, generative AI, 3D printing and a training center equipped with a digital twin – a virtual model of the shop floor manufacturing process systems – to accelerate new employee training and simulate process changes before they are implemented.

“This level of investment and commitment speaks so powerfully to the work we do here in Durham,” said Amanda Taylor, vice president and plant manager at the Merck Manufacturing Division site in Durham. “To see the pride and the energy of the people who work here and are helping drive this evolution in our capabilities is just phenomenal.”

Please visit the Merckmedia library for images and b-roll of the new Durham facility.

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit http://merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (http://sec.gov).

https://markets.ft.com/data/announce/detail?dockey=600-202503110645BIZWIRE_USPRX____20250311_BW491578-1

#dcvax $nwbo #gbm

Company Announcements :

Merck & Co IncMerck Unveils New Facility to Increase Vaccine Production Capacity
Mar 11 2025

Opening highlights effort to expand U.S. manufacturing through a $1 billion investment

DURHAM, N.C.--(BUSINESS WIRE)--Mar. 11, 2025-- Merck… pic.twitter.com/IBvpp1eZ9F— Peter Davis (@peter_brit) March 11, 2025

As I said, the court case is DOA, as are most things in nwbo land.

At the end of time after Linda Grifter decides she has stolen enough cash.

You are quite right, Guzzi; he should have heard of DCVaxI and he should be able to fund the treatment.

If he is sceptical all he has to do is read the scientific papers that have come out of UCLA and NWBO which, with his scientific mind, should assuage his scepticism. If he remains a sceptic he will go to his death a sceptic whereas having the treatment will show him how wrong he was to be sceptical.

You are so full of it.

I'm sure that they would love to treat the Professor in one of their trials - but if it were you (and you were being honest with yourself), would you opt for a punt that this early stage treatment which has not yet produced any real world results beyond demonstrating that it increases T-Cell infiltration of the tumour, or would you choose DCVax-L which is currently showing >50% success rate with its combinations and which is already available for use?

He seems to be a pathological liar, just like LP, LG, and DI.

Understaffed, are you kidding me? The reason why they took over 3 years to submit MAA and double/triple check the application before submitting to the UK was so that they could apply to multiple RAs. They simply lied to investors at that point.

When your existence and ability to turn profit depends on US approval, you do whatever it takes to submit an application and not come up with excuses. This is why no credible institutions would back them.

They won’t be able to hide anymore. The lies and dangling of carrots catches up soon.

They are likely to get sued in Q4 this year. A few shareholders that care about ROI and opportunity cost are going to come together and expose the lies. Thats all I will say.

What he is saying is that DCVAX wont get approved by the FDA if that promising pathway act is not passed. It’s not about Flaskworks and volume manufacturing as some liars and pumpers here claim!

As I said, LP and the team are likely to get sued later this year. The lies and dangling of carrots catches up at around the 5 year anniversary of data lock.

Surely the good Professor Richard Scolyer have heard of DC-Vax?

He should be able to raise money, a prominent person like that, for a vaccine in the UK?

Maybe he is sceptical about the vaccine?

But he don't have anything to lose, so?

#dcvax $nwbo #gbm pic.twitter.com/rnxVOVYHeO— Peter Davis (@peter_brit) March 11, 2025

Wiz888999
@ODB123
🔥🚨 DTCC is officially in the HOT SEAT! 🚨🔥

Court orders them to hand over records on daily failures to deliver, clearing data, and all that behind-the-scenes broker magic.

The receipts are coming out, and someone’s about to get BUSTED. 🍿👀

This ain’t just a nothingburger it’s a full-course meal. Who’s hungry? 😏

🔥🚨 DTCC is officially in the HOT SEAT! 🚨🔥

Court orders them to hand over records on daily failures to deliver, clearing data, and all that behind-the-scenes broker magic.

The receipts are coming out, and someone’s about to get BUSTED. 🍿👀

This ain’t just a nothingburger… https://t.co/Pg5TEsPpRX— Wiz888999 (@ODB123) March 11, 2025

Thanks, Doc.

I would hope and expect that by now any neurosurgeon worth his salt would know that material for possible use in the manufacture of DVax-L has specific storage criteria.

I just find the whole thing sad; an eminent man apparently turning his back on a non-noxious treatment that might save his life and the only thing that might cause him any discomfort is a leukapheresis and a minimum of 3 intradermal injections in his arm.

Gary, I believe, I suspect, I assume that the company will get aproval by next week...

March-June 2024.... It goes on forever...

This is less than 5% of his wrong "believe" or predictions...

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174102970

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174191335

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174191473

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174249133

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174408575

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174434425

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174441114

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174971286

Just non stop wrong, over and over and over again...
Doesnt beat Dstock, but almost does due to the high amount of them.

DocLee,

That's the point of my post. It strikes me that some of the them knew about DCVax-L. Did you see how many papers Georgina V. Long coauthored with Antoni Ribas who is Dr. Liau's colleague? Did they suggest DCVax-L to Dr. Scolyer? Is David Reardon among the coauthors? Can you believe he and Antonio Chiocca wrote a critical article tantamount to a hitting piece published on the Thanksgiving?
https://academic.oup.com/neuro-oncology/article/26/2/211/7444576

According to the post from DD, there are over 62 long term survivors. And the analysis done by NCI researchers along with Dr. Liau clearly shows that for the most life-threatening subtype of GBM, DCVax-L has the most significant efficacy. Here we are talking about DCVax-L alone case.

The current combo trial is still enrolling patients and it only needs at minimum 2 gram tumor tissue. I see no reason why he cannot give it a try.

Here is the first 32 minutes of the Webinar, WITHOUT the much talked about Q&A, which had explosive information.

The Q&A is summed up on the image below.https://t.co/z7cB2JMaNS pic.twitter.com/5dnOq8YYRP— 🇩🇰 The Danish Dude 🇩🇰 (@FlemmingBruce) March 10, 2025

If you're correct about every question being answered, it could be any day. I wish I were completely sure that you're right.

I would suspect that if any questions are still being answered, they may very well be answered by contractors which NWBO doesn't have full control of, perhaps even from Doctors or others involved with the clinical trial, or perhaps even with compassionate use.

Gary

Where would we be if all 4 regulators approved DCVax-L, but without approval of the EDEN, we could provide roughly 1000 batches of vaccine to 300,000+ new patients who're newly diagnosed worldwide each year.

The key, since we acquired it in 2020, is getting the EDEN working in such a way that it meets the regulators demand. I frankly have no idea how long it took the scientists at FlaskWorks to reach the point that they could consistently make DCVax-L, I believe that's done. Now they must prove it.

I think the EDEN is a very different device today than it was when FlaskWorks was acquired. Only recently as I understand it, the company finalized exactly how the unit would be made and packaged. I cannot say if one or more companies are prepared to mass produce the EDEN unit, but I've got to believe the company is working on it, if they don't have the capability already. I frankly don't know the capability at FlaskWorks themselves, can they make the EDEN unit there themselves, or does it require contractors, others may know, I don't. I don't believe that have mass production capability, but I don't know that's a fact.

It's my belief that in time FlaskWorks will become its own profit center. I think it will be monitoring every EDEN unit that's in service, and will be responsible for their maintenance and any upgrades deemed to be necessary. In addition, I'd not be surprised if they create other similar units for making other personalized units for making products for other companies whose products don't compete with NWBO. They would perform the same services for these other companies and as I said, become a substantial profit center for the company.

I'm not speaking of now, but perhaps a decade from now we may all be surprised by how much the FlaskWorks division is bringing in.

Gary

Yes

He did not say DCVax-L was approved.

Doclee,

Phenotype testing should be done as well because if his GBM has a mesenchymal signature now, like many convert to at recurrence, L plus Poly ICLC have a much better chance to work. Then again, everything would still hinge on whether or not the resected material was properly stored too. Best wishes.

HappyLibrarian,

Funny how quickly it corrected once noted and shared with another about; ). Best wishes.

If approval denied what then, is it the end of NWBO and my money.

Data lock was over 4.5 years ago but the trial was over 8 years ago. This is the world record.....this is what happens when ceco priorities are building out her own CDMO(s) x 2.

You know you made it when you have an AI troll responding to your every post. Gotta keep truth from coming out by drowning you out.

No, but there is a time capsule Saturday event coming soon.

Woah ..... NWBO still ISN'T approved?  I'm shocked!!

Any regulator questions should have been adressed by now. Any guess on how much longer till approval?

Great. Let them focus on their branch of research, and not chime in in areas, they have no expertise in.

I'll repeat again that you cannot apply until you have a commercial production facility that will be ready for inspection by the regulator. The company doesn't have any such facility until such time as the EDEN can be used to make the vaccine.

20 tiny cleanrooms in Sawston don't constitute such a facility, they're adequate to get the UK started, but not the US or other more populous places.

If I'm right about 20 cleanrooms, each one is capable of making roughly 50 batches a year. That's 1000 total patients that could be treated in one year. Currently according to Google there are over 300,000 new cases of GBM annually worldwide, 1000 is less than the rounding error. It may be enough to get the UK started, but demand should require the EDEN there very shortly as well.

Once we've learned when approval of the EDEN is anticipated we'll know when filing with other regulators might be anticipated.

I'm not saying EDEN approval must occur prior to filing. I'm saying that it must be approved by a few months into the process when inspector can check the commercial production facilities. Clearly the company would need to be practically certain of EDEN approval before filing with one or more regulator.

Gary

Ego comes to mind.

zero82,

Thanks for reposting that again 😶

Yes, “relentless execution” …



✅️ She executed her plan to acquire, develop, and secure a valuable patent-fortified manufacturing technology called EDEN. (Flaskworks strategic acquisition was relatively recent in 2020).

✅️ She executed her plan to get a prestigious and reputable medical journal to publish an independently peer-reviewed analysis of the P3.

✅️ She executed her plan to acquire the commercial rights to ANOTHER patent-fortified novel dendritic cell technology that’s in PII trials funded by the U.S. DoD at Roswell Park.

✅️ She executed her plan to recruit Linda Liau to join the SAB at NWBO.

✅️ She executed her plan to secure a PIP approval and an MIA approval from MHRA followed by a voluminous MAA submission.

✅️ She executed her plan to recruit Dr. Ashkan to run the DCVax-L trial in Europe and lead the UK Specials Program that has the ongoing support of the MHRA.




“His work on brain cancer vaccines received the top presentation award by the British Neuro-Oncology Society in 2022 and promises to impact the care of patients with brain tumours worldwide.”
Consultant Neurosurgeon at @KingsCollegeNHS, Professor Keyoumars Ashkan, receives an MBE for services to neurosurgery.
 
In 2020, he removed patient Dagmar's brain tumour while she played her violin throughout the surgery. 👇pic.twitter.com/H2Z4LZic0h— NHS London (@NHSEnglandLDN) December 31, 2024
https://thejns.org/caselessons/view/journals/j-neurosurg-case-lessons/8/2/article-CASE24112.xml

https://www.kcl.ac.uk/news/professor-keyoumars-ashkan-awarded-mbe-in-kings-new-years-honours

https://www.bbc.com/news/uk-england-london-66378288

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175903429

A company that was serious would have also submitted to another regulatory agency such as FDA and EU. Again, the trial got over 4.5 years ago, but no guidance on US application. US is 20 X of UK in terms of revenue potential. US represents over 50% of the world’s revenue in oncology therapies.
One reason could be that they're understaffed and unable to handle both agencies at the same time. They might want to move forward with the next steps, thinking that MHRA approval will improve their chances with various agencies and approvals. One thing is certain: all of us—investors and patients—have lost out on the vaccine due to these delays.